Last reviewed · How we verify
Brentuximab
This drug has been discontinued. Further clinical information is unavailable due to the discontinuation of the trial.
At a glance
| Generic name | Brentuximab |
|---|---|
| Also known as | Brentuximab Vedotin, Adcetris |
| Sponsor | University of Arizona |
| Target | Tumor necrosis factor receptor superfamily member 8, Tubulin beta |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | discontinued |
Approved indications
- Anaplastic large T-cell systemic malignant lymphoma
- CD30-positive peripheral T-cell lymphoma
- Cutaneous Tcell lymphoma
- Hodgkin's disease
Common side effects
Key clinical trials
- A Phase 2, Open-label Study of Brentuximab Vedotin in Patients With CD30-positive Nonlymphomatous Malignancies (Phase 2)
- Special Drug Use Surveillance for Adcetris Intravenous Infusion 50 Milligrams "Relapsed or Refractory CD30-positive Peripheral T Cell Lymphoma or Hodgkin Lymphoma (Only Pediatric Patients)" (N/A)
- An Open Label Phase I Study of Brentuximab Vedotin Plus TAK228 for Patients With Relapsed/Refractory Classical Hodgkin Lymphoma, Anaplastic Large Cell Lymphoma and Other CD30+Peripheral T-Cell Lymphom (Phase 1)
- A Phase 2 Study of Nivolumab and Brentuximab Vedotin Consolidation After Autologous Stem Cell Transplantation in Patients With High-Risk Classical Hodgkin Lymphoma (Phase 2)
- A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T-cell Lymphoma in First Salvage Setting: the BBV Regimen. (Phase 2)
- Pilot Study Using Induction Chemo-immunotherapy Followed by Consolidation With Reduced Toxicity Conditioning and Allogenic Stem Cell Transplant in Advanced Stage Mature Non-anaplastic T-Cell or NK Lym (EARLY/Phase 1)
- Phase I Study of Mogamulizumab (M) in Combination With Brentuximab Vedotin (BV) in Previously Treated Cutaneous T Cell Lymphoma (CTCL) and Mycosis Fungoides (MF) (Phase 1)
- Phase I Trial of Brentuximab Vedotin for Refractory Chronic Graft-vs.-Host Disease (GVHD) (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Brentuximab CI brief — competitive landscape report
- Brentuximab updates RSS · CI watch RSS
- University of Arizona portfolio CI